Accelerating the Adoption Curve: Improving Patient Outcomes in Psychiatry

ALISO VIEJO, Calif., Sept. 12, 2014 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO): George C. Carpenter, CEO of CNS Response will be speaking at the upcoming Frost and Sullivan Growth, Innovation and Leadership conference: "The Future of Value Based Care Delivery," as part of the expert panel on "Prospering in a Radically New Healthcare Landscape." The session takes place on Tuesday, September 16th from 1:50pm to 3:20pm at the Fairmont Hotel in San Jose, CA.

"Big data can now be used to solve a real clinical problem, trial and error prescribing, now." Carpenter will discuss the company's technology, PEER, a recommendation engine which delivers objective data to physicians treating mental illness. With approximately 30 million patients taking anti-depressants, PEER addresses a significant unmet need.

General Peter Chiarelli, retired Army Vice Chief, thinks CNS Response's technology will help soldiers and veterans suffering from mental illness: "I can't help but think that the data from PEER is going to lead us to targets that will only improve which drugs we're prescribing for patients."

About CNS Response

CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 37,000 outcomes for 9,800 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy which is the dominant approach for treatment resistant patients.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit Medical professionals interested in learning more can contact CNS Response at

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Copyright 2014 CNS Response | | (855) 273-2445

CONTACT: Media Relations: Lauren Jenkins Scoutcomms 1-877-565-3323

Source:CNS Response